IX
ORIX Corporation
There isn't enough reported data to score IX yet.
IX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| N/A | |
| N/A |
IX's profitability is currently strong. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like IX.
IX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 5.8x | $34.08 | — |
| Cheap | 8.7x | $51.41 | +51% |
| Fair | 11x | $67.56 | +98% |
| Expensive | 14x | $82.03 | +141% |
Historical ranges are pointers, not guarantees.
IX's PE is 5.8x, but its earnings don't support one, so it isn't a reliable read right now.
IX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong decline | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect IX's earnings and revenue to decline, with profitability weakening.
IX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $5.90 | +143% |
| Q1 2026 | $2.49 | +122% |
| Q1 2025 | $1.12 | +203% |
| Q1 2024 | $0.37 | +28% |
| Q4 2023 | $0.30 | -9.1% |
| Q3 2023 | $0.30 | 0% |
| Q1 2023 | $0.29 | -9.4% |
| Q4 2022 | $0.33 | +22% |
IX's earnings per share have jumped to their highest in five years: $5.90 over the past year, up from $0.37 the year before.
IX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.5B | +7% |
| Q1 2026 | $11.1B | +20% |
| Q3 2025 | $9.8B | +11% |
| Q1 2025 | $9.2B | -48% |
| Q3 2024 | $8.8B | +3.2% |
| Q1 2024 | $17.6B | +319% |
| Q4 2023 | $4.3B | +7.6% |
| Q3 2023 | $8.5B | -0.4% |
IX's revenue is recovering but still below its 2024 peak: $10.5B last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +0.3 points |
| Q1 2026 | 12% | -0.7 points |
| Q3 2025 | 16% | +1.3 points |
| Q1 2025 | 9.2% | -2.9 points |
| Q3 2024 | 14% | +2.6 points |
| Q1 2024 | 13% | -1.2 points |
| Q4 2023 | 14% | +3.3 points |
| Q3 2023 | 12% | +9 points |
IX's operating margin was 14% last quarter, about level with the same quarter a year ago.
IX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +4.6% |
| Q1 2026 | $4.5B | +9.3% |
| Q3 2025 | $3.6B | +0.5% |
| Q1 2025 | $4.1B | -44% |
| Q3 2024 | $3.6B | +4.1% |
| Q1 2024 | $7.3B | +283% |
| Q4 2023 | $2B | +15% |
| Q3 2023 | $3.5B | +143% |
IX's free cash flow was $16B over the past year, down 2.2% from the year before. Free cash flow isn't a meaningful measure for financial services companies like IX.
IX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.4% | -27M shares |
| 1 year | -81% | -4.7B shares |
| 3 years | -82% | -4.9B shares |
| 5 years | -83% | -5.3B shares |
| Available history | -83% | -5.4B shares |
IX has 1.1B diluted shares, down 81% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $933.4M |
| Q1 2026 | $490.9M |
| Q3 2025 | $449.3M |
| Q1 2025 | $113.5M |
| Q3 2024 | $222M |
| Q1 2024 | $313.4M |
| Q4 2023 | $116.1M |
| Q3 2023 | $197.3M |
IX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q3 2025 | 6.8x | High |
| Q1 2025 | 6.9x | High |
| Q1 2024 | 7.1x | High |
| Q4 2023 | 7.2x | High |
| Q3 2023 | 7.4x | High |
| Q1 2023 | 6.7x | High |
IX's net debt is about 5.7 years of its operating earnings (EBITDA), down from 7.1 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IX.
IX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.3 | Neutral |
| Stochastic | 11.3 | Oversold |
IX's weekly RSI is 38 (neutral) and its Stochastic is 11 (oversold).
IX PE vs Financial Services Sector
| Metric | IX | Sector median | Relative |
|---|---|---|---|
| PE | 5.8x | 13x | 56% below |
| PE % | 5 | 63 | 58 pts below |
IX is trading at 5.8x earnings, a 56% discount to the Financial Services sector's median of 13x, though its earnings don't support one.
IX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.6 | 6.8% below |
| 20 week MA | $38.4 | 11% below |
| 50 week MA | $35.1 | 2.9% below |
| 100 week MA | $28.9 | 18% above |
| 200 week MA | $24.4 | 40% above |
IX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 40% above its 200-week average.
IX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.6 | $14.8 | -11% |
| 2021 | $14.8 | $20.2 | +36% |
| 2022 | $20.2 | $16.3 | -19% |
| 2023 | $16.3 | $18.7 | +15% |
| 2024 | $18.7 | $21.4 | +15% |
| 2025 | $21.4 | $29.4 | +37% |
| 2026 YTD | $29.4 | $34.1 | +16% |
IX has finished higher in four of the last six years. It's up 16% so far in 2026.